Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination.

Trial Profile

Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs GP120-depleted HIV-1 vaccine (Primary) ; Antiretrovirals; HIV vaccine vCP1452
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Feb 2016 According to an Immune Response media release, the company has received a Complete Response Letter from the US FDA for its HIV vaccine Remune HIV-1 Immunogen therapeutic vaccine for adults.
    • 28 Jul 2015 According to a media release, Immune Response BioPharma's FDA BLA for Remune in combination with current HAART drugs for the treatment of patients with HIV infections was accepted on 27th March 2015. The PDUFA date has been changed to 26th November 2015.
    • 21 May 2012 Last checked against ClinicalTrials.gov record (Parent trial: NCT00005758).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top